secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K/A
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001558370-24-000770
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris discloses interim CEO Neal Walker's compensation: $500k salary, equity awards
--------------------------------------------------------------------------------

- Douglas Manion stepped down as CEO/President effective Jan 16, 2024; no disagreement.
- Neal Walker appointed Interim CEO; receives $500,000 base salary, bonus eligible at 60% of base.
- Granted stock option for 497,000 shares at $1.20 per share, vesting monthly over 15 months.
- Also granted RSU for 142,000 shares with same 15-month monthly vesting and change-in-control acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/0001558370-24-000770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/acrs-20240115x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer